#AHA20 – Randomized trial: In patients with refractory hypercholesterolemia, the use of Evinacumab significantly reduced the LDL levels. Larger studies with patient-relevant outcomes are needed.

Evinacumab in Patients with Refractory Hypercholesterolemia – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Evinacumab in Patients With Refractory Hypercholesterolemia – Evinacumab for Refractory Hypercholesterolemia – American College of Cardiology

Commentary on Twitter

In patients with hypercholesterolemia that is refractory to statin and PCSK9 inhibitor therapy, the use of evinacumab reduced plasma lipid levels by 50%. #AHA20

— NEJM (@NEJM) November 15, 2020